Generics & Biosimilars | Association for Accessible Medicines
COVID-19 and AAM - FAQ's and resources from the U.S. generics and biosimilars industry.
  • ""
    Oppose New “Buy American” Restrictions
    New “Buy American” requirements on medicines would limit patient access to affordable medicines and increase the risk of drug shortages during the COVID-19 pandemic.
  • ""
    COVID-19 and AAM: FAQs
    The coronavirus (COVID-19) pandemic is disrupting everyday life around the world and imposing unprecedented stress on our health care system. Here are some responses and resources from the U.S. generics and biosimilars industry.
  • COVID-19 Response - Patient Access to Medicines
    COVID-19: Ensuring Americans Have Access to Their Medicines
    America’s generic and biosimilar manufacturers are committed to meeting the health care needs of patients in the U.S.

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.